Theodore Martinot, Ph.D.

Theo Martinot brings to FogPharma almost two decades of leadership experience in drug development from preclinical phase to New Drug Application and has worked on successful drugs, including Incivek (telaprevir) and Copiktra (duvelisib). As vice president of pharmaceutical development at FogPharma, he enables the supply of Helicon™ peptides drug substances and drug products to the clinic and helps build a platform capable of empowering this new modality.

Prior to joining FogPharma, Theo was a senior director of chemistry at Infinity Pharmaceuticals, where he worked to establish a commercial-ready process for the manufacturing of eganelisib, and led preclinical and clinical collaboration discussions for the drug candidate. Prior to that, he was a member of the discovery process chemistry group at Merck, where he contributed to multiple programs in oncology and neuroscience. Prior to Merck, Theo held positions of increasing responsibility at Infinity and started his career at Vertex Pharmaceuticals.

Theo holds a Ph.D. in organic chemistry and a B.S. in chemistry from the University of Florida.